Novelix Pharmaceuticals Announces Preferential Allotment Following Warrant Conversion
Novelix Pharmaceuticals Ltd has disclosed the allotment of equity shares consequent to the conversion of warrants during a preferential allotment that took place on May 29, 2026. The transaction involved members of the promoter group acquiring new shares.The acquisition was made by Gattu Gnana Prakash, Arati Gattu, and Neha Gattu, who received various quantities of equity shares in Novelix Pharmaceuticals Ltd through the conversion process.
Details regarding the allotment and the status of the acquirers are provided below:
| Promoter Name | Shares Allotted (Warrant Conversion) |
|---|---|
| Gattu Gnana Prakash | 50,000 Equity Shares |
| Arati Gattu | 100,000 Equity Shares |
| Neha Gattu | 100,000 Equity Shares |
The allotment led to a change in the promoter group's stake and affected the capital structure of the company. Before the transaction, the combined holding of the acquirers was reported at 2.51% of the diluted share/voting capital. Post-acquisition, the total holding stood at 2.09% (voting capital) and 2.51% (diluted share/voting capital).
The financial figures pertaining to the pre- and post-acquisition status of Novelix Pharmaceuticals Ltd are as follows:
| Metric | Before Acquisition | After Acquisition |
|---|---|---|
| Total Voting Capital | Rs. 210,850,000/- (constituting 21,085,000 Equity Shares of Rs. 10/- each) | Rs. 238,950,000/- (constituting 23,895,000 Equity Shares of Rs. 10/- each) |
| Total Diluted Share/Voting Capital | N.A. | Rs. 272,700,000/- |
The acquisition mode utilized in this transaction was the conversion of warrants into Equity Shares issued on a Preferential Allotment Basis.
Stock Price Movement
As of 10:32, Novelix Pharmaceuticals Ltd is edging higher at ₹55.97, showing a healthy gain of 6.27% in its shares. The stock has seen volatile trading during the session, moving through an intraday range bounded by a low of ₹51.30 and a high of ₹57.50.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.